Skip to main content
. 2018 Sep 5;16:139. doi: 10.1186/s12916-018-1130-7

Table 1.

Overview of cost-benefit analysis (CBA) approaches to monetise benefits

Method Rationale Major limitations and uncertainties How we accounted for methodological uncertainties
Human capital ▪ Individual perspective
▪ Indirect benefits are productivity losses avoided by prevented or reduced morbidity and mortality
▪ Productivity losses are valued by individual’s cumulative income over the entire time absent from work
▪ Considers productivity loss incurred only by economically active individuals
▪ Leads to biased decisions in favour of high-income earners and economically active individuals
▪ Sensitivity analysis was conducted to include homemakers in the calculation of productivity loss averted
Friction cost ▪ Employer perspective
▪ Indirect benefits are productivity losses avoided by prevented or reduced morbidity and mortality
▪ Productivity losses are valued by individual’s gross earnings over the friction period
▪ Assumes there always exists some level of involuntary unemployment
▪ The sick/deceased worker is replaced by another worker who otherwise would have remained unemployed
▪ Disease- and job-specific data needed for estimating the friction period are often unavailable
▪ Considers productivity loss incurred only by economically active individuals
▪ Leads to biased decisions in favour of high-income earners and economically active individuals
▪ Sensitivity analysis was conducted to vary friction period – 55, 69 and 90 days – to account for uncertainties regarding the vacancy duration
▪ Sensitivity analysis was conducted to include homemakers in the calculation of productivity loss averted
Value of a statistical life (VSL): Revealed Preference ▪ Individuals implicitly reveal how much they value mortality risk reduction in real markets (e.g. wage-risk trade-offs)
▪ VSL is derived from observed behaviours
▪ Focus is mostly on job-related risks among working-age population, which largely result from injuries rather than illnesses ▪ A range of VSL estimates, including a VSL for cancer after adjusting for a 10-year latency period was used
VSL: Stated Preference ▪ Use contingent valuation with hypothetical scenario (i.e. surveys) to derive VSL ▪ Extra effort may be required to encourage survey participants for valid responses ▪ A range of VSL estimates, including one from a willingness-to-pay (WTP) study done in cervical cancer patients was used
Monetisation of quality adjusted life years (QALYs) (QM) ▪ QALY captures a broad range of health benefits
▪ QALY can be monetised by multiplying the WTP with gains in QALYs
▪ Individuals cannot be expected to have a constant rate of substitution between QALYs and wealth ▪ Our QM approach with a £23,000/QALY WTP is analogous to NICE’s cost-effectiveness reference case, which has a cost-effectiveness threshold of £20,000–£30,000/QALY [9]